The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ELCC 2016 | Predictive models of tumor response to chemotherapy and radiotherapy in NSCLC
At the 6th European Lung Cancer Conference (ELCC), held in Geneva, Switzerland, from 13–16 April 2016, Kenneth O’Byrne, MD, from Princess Alexandra Hospital, Queensland University of Technology, Brisbane, Australia, discusses biomarkers, including biomarkers of DNA repair and related pathways, for predicting treatment response to chemotherapy and radiotherapy in patients with non-small cell lung cancer (NSCLC).
